# Empirical Data Enhancement Analysis
## Target Plot Types: Incidence, Resistance, and Mortality

**Analysis Date**: September 18, 2025  
**Target Metrics**: 
1. `incidence_of_infection` 
2. `mean_any_r_by_drug_for_each_bacteria`
3. `death_rate_by_bacteria_region`

---

## Current Data Coverage Assessment

### 📊 Current Empirical Data Status

| Metric Type | File | Records | Real Data | Synthetic Data | Coverage Gap |
|-------------|------|---------|-----------|----------------|--------------|
| **Incidence** | `calibration_infection_incidence_empirical.csv` | 18,565 | 0 records | 18,564 records | **~100% synthetic** |
| **Resistance** | `calibration_resistance_empirical.csv` | 157,795 | 4 records | 157,791 records | **~99.997% synthetic** |
| **Deaths** | `calibration_deaths_empirical.csv` | 18,565 | 0 records | 18,565 records | **~100% synthetic** |

### 🚨 Critical Findings
- **Incidence data**: 100% synthetic epidemiological models
- **Resistance data**: Only 4 real empirical records out of 157,795 total
- **Mortality data**: 100% synthetic fallback patterns
- **Overall empirical coverage**: <0.01% across all three metrics

---

## Enhanced Data Acquisition Strategy

### 🎯 **PRIORITY 1: Incidence of Infection Data**

#### **Target Data Sources**
1. **WHO GLASS (Global)**
   - **Coverage**: 120+ countries, major bacteria
   - **Access**: Free API and downloads
   - **URL**: `https://www.who.int/initiatives/glass`
   - **Data**: Annual incidence reports by bacteria and region
   - **Expected Coverage**: 60-70% of major bacteria

2. **ECDC TESSy (Europe)**
   - **Coverage**: 31 EU/EEA countries
   - **Access**: Public surveillance reports
   - **URL**: `https://www.ecdc.europa.eu/en/surveillance-atlas-infectious-diseases`
   - **Data**: Detailed incidence by bacteria, age, region
   - **Expected Coverage**: 90% for European data

3. **CDC NNDSS (North America)**
   - **Coverage**: United States surveillance
   - **Access**: Public health data
   - **URL**: `https://www.cdc.gov/nndss/`
   - **Data**: Notifiable disease incidence
   - **Expected Coverage**: 70% for US data

4. **National Systems**
   - **Australia**: NNDSS Australia
   - **Canada**: PHAC surveillance
   - **Japan**: NESID system
   - **Brazil**: SINAN system

#### **Implementation Plan**
- **Phase 1**: WHO GLASS API integration (2-3 weeks)
- **Phase 2**: ECDC TESSy data extraction (1-2 weeks)
- **Phase 3**: National system integration (3-4 weeks)
- **Expected Improvement**: 40-60% real data coverage

---

### 🎯 **PRIORITY 2: Resistance Data Enhancement**

#### **Target Data Sources**
1. **WHO GLASS AMR Module**
   - **Coverage**: Global resistance surveillance
   - **Access**: Public AMR reports
   - **Data**: Resistance percentages by drug-bacteria pairs
   - **Expected Coverage**: 50-60% of combinations

2. **ECDC EARS-Net**
   - **Coverage**: European resistance surveillance
   - **Access**: Annual reports and interactive database
   - **URL**: `https://www.ecdc.europa.eu/en/antimicrobial-resistance/surveillance-and-disease-data/data-ecdc`
   - **Data**: Detailed resistance breakdowns
   - **Expected Coverage**: 80% for European combinations

3. **CDC NARMS (US)**
   - **Coverage**: US resistance monitoring
   - **Access**: Public reports
   - **Data**: Resistance trends by bacteria
   - **Expected Coverage**: 60% for US data

4. **ATLAS Global Database**
   - **Coverage**: Comprehensive global resistance data
   - **Access**: Academic/commercial partnerships
   - **Cost**: Potential licensing required
   - **Expected Coverage**: 85-90% of combinations

#### **Implementation Plan**
- **Phase 1**: WHO GLASS AMR integration (2-3 weeks)
- **Phase 2**: ECDC EARS-Net data extraction (2 weeks)
- **Phase 3**: Academic partnerships for ATLAS (4-6 weeks)
- **Expected Improvement**: 50-75% real data coverage

---

### 🎯 **PRIORITY 3: Mortality Data Enhancement**

#### **Target Data Sources**
1. **Global Burden of Disease (GBD) Study**
   - **Coverage**: Global mortality by infectious diseases
   - **Access**: Public research data
   - **URL**: `https://ghdx.healthdata.org/gbd-results-tool`
   - **Data**: Deaths by cause, region, year
   - **Expected Coverage**: 70-80% of bacteria-region combinations

2. **WHO Global Health Observatory**
   - **Coverage**: Global mortality statistics
   - **Access**: Public health data
   - **URL**: `https://www.who.int/data/gho`
   - **Data**: Infectious disease mortality
   - **Expected Coverage**: 60% coverage

3. **National Vital Statistics**
   - **Coverage**: Country-specific death certificates
   - **Access**: Public health departments
   - **Data**: ICD-10 coded mortality data
   - **Expected Coverage**: 40-50% for major countries

4. **Hospital Mortality Studies**
   - **Coverage**: ICU and hospital mortality rates
   - **Access**: Published literature and databases
   - **Data**: Case fatality rates by bacteria
   - **Expected Coverage**: 30-40% focused coverage

#### **Implementation Plan**
- **Phase 1**: GBD data integration (3-4 weeks)
- **Phase 2**: WHO mortality data extraction (2 weeks)
- **Phase 3**: Literature-based mortality rates (4-5 weeks)
- **Expected Improvement**: 60-70% real data coverage

---

## 📈 Expected Outcomes by Phase

### **Phase 1 Completion (6-8 weeks)**
- **Incidence**: 40% real data (vs current 0%)
- **Resistance**: 50% real data (vs current <0.01%)
- **Mortality**: 60% real data (vs current 0%)
- **Overall**: 50% improvement across all metrics

### **Phase 2 Completion (12-15 weeks)**
- **Incidence**: 65% real data
- **Resistance**: 70% real data  
- **Mortality**: 75% real data
- **Overall**: 70% real empirical coverage

### **Phase 3 Completion (20-24 weeks)**
- **Incidence**: 75% real data
- **Resistance**: 85% real data
- **Mortality**: 80% real data
- **Overall**: 80% real empirical coverage

---

## 💰 Implementation Costs

### **Free Sources (Phase 1)**
- **Staff time**: 6-8 weeks full-time equivalent
- **Infrastructure**: API integration and data processing
- **Cost**: $0 for data, ~$15-20K in development time

### **Academic Partnerships (Phase 2)**
- **ATLAS access**: Potential academic collaboration
- **Literature access**: University subscriptions
- **Cost**: $5-10K in partnership development

### **Commercial Sources (Phase 3)**
- **IQVIA MIDAS**: $50-200K annually (if needed)
- **Commercial surveillance**: $10-50K per dataset
- **Cost**: $60-250K depending on scope

---

## 🚀 Immediate Next Steps

### **Week 1-2: Foundation**
1. Set up WHO GLASS API access
2. Establish ECDC data extraction pipeline
3. Create automated data harmonization scripts

### **Week 3-4: Implementation**
1. Implement WHO GLASS integration
2. Process ECDC surveillance data
3. Validate data quality and coverage

### **Week 5-6: Integration**
1. Update empirical calibration files
2. Test integration with analysis pipeline
3. Validate improvement in plot quality

### **Week 7-8: Validation**
1. Compare simulation outputs with enhanced data
2. Quantify improvement in empirical coverage
3. Document methodology and results

---

## 📊 Success Metrics

1. **Coverage Improvement**: Target 50-80% real data across all three metrics
2. **Data Quality**: Reduce reliance on synthetic fallbacks by 80%
3. **Regional Balance**: Achieve representation across all 6 simulation regions
4. **Temporal Coverage**: Span key antibiotic introduction periods (1940-2020)
5. **Validation**: Improved correlation with known epidemiological patterns

---

## 🔄 Maintenance Strategy

1. **Quarterly Updates**: Regular data refreshes from primary sources
2. **Quality Monitoring**: Automated validation of new data
3. **Source Diversification**: Continuous addition of new data sources
4. **Community Engagement**: Collaboration with surveillance networks

---

This enhancement strategy should dramatically improve the empirical foundation of your AMR simulation, providing much more realistic and validated inputs for the three key plot types you're focusing on.